Shares of Fulcrum Therapeutics (NASDAQ:FULC) rose on Friday after Leerink Partners upgraded the Cambridge, Massachusetts-based biopharma, citing a favorable risk-reward setup ahead of a trial readout ...

This could give Novartis' drug a slight advantage. However, Leerink Partners analyst Joseph Schwartz said the FDA will consider removing the liver monitoring requirement for Filspari in late August.

Playing defense; shocking stuff; to the cleaners; and other highlights of recent tax cases.

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the ...

Joseph Schwartz, 65, pleaded guilty in January 2024 to federal indictment charges of willfully failing to pay employment taxes withheld from his employees and willfully failing to file an annual ...

Joseph Schwartz owned and operated Skyline Management Group LLC, originally headquartered in Wood-Ridge, which ran health care and rehabilitation facilities nationwide. Schwartz pleaded guilty in ...

A new sales organization for Israel bonds, under the direction of Dr. Joseph J. Schwartz, executive vice-chairman of the United Jewish Appeal, is now in the process of formation in this country ...